Circulating antiretinal antibodies predict the outcome of anti-VEGF therapy in patients with exudative age-related macular degeneration

Acta Ophthalmologica

Volumn 90, Issue 1, 2012, Pages

  Kubicka Trzäska, Agnieszka ^a   Wilańska, Joanna ^a   Romanowska Dixon, Bozena ^a   Sanak, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

age related macular degeneration; antiretinal autoantibody; antivascular endothelial growth factor therapy; bevacizumab

Indexed keywords

ANTIBODY; BEVACIZUMAB; RETINAL ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIANGIOGENIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPHTHALMOSCOPY; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84856528896     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02237.x     Document Type: Article

References (23)

1. Bressler NM, Bressler SB, &, Fine SL, (1988): Age-related macular degeneration. Surv Ophthalmology 32: 375-413.
2. Brown DM, Kaiser PK, Michels M, et al., (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444. (Pubitemid 44511558)
3. Chant SM, Hechenlively J, &, Meyers-Elliott RH, (1985): Autoimmunity in hereditary retinal degeneration. I. Basic studies. Br J Ophthalmol 69: 19-24. (Pubitemid 15083460)
4. Cherepanoff S, Mitchell P, Wang JJ, &, Gillies MC, (2006): Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin Experiment Ophthalmol 34: 590-595.
5. Coutinho A, Kazatchkine MD, &, Avrameas S, (1995): Natural autoantibodies. Curr Opin Immunol 7: 812-818. (Pubitemid 26038522)
6. Dumonde DC, Kasp-Grochowska E, Banga JP, et al., (1985): Autoimmune mechanisms in inflammatory eye disease. Trans Ophthalmol Soc U K 104: 232-238. (Pubitemid 15104144)
7. Eltabbakh GH, Hoogerland DL, &, Kay MC, (1995): Paraneoplastic retinopathy associated with uterine sarcoma. Gynecol Oncol 58: 120-123.
8. Fine SL, Berger JW, Maguire MG, &, Ho AC, (2000): Age-related macular degeneration. N Engl J Med 342: 483-492. (Pubitemid 30100237)
9. Gurne DH, Tso MO, Edward DP, &, Ripps H, (1991): Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology 98: 602-607.
10. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, &, Mullins RF, (2001): An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732. (Pubitemid 32918285)
11. Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, &, Grus FH, (2007): Analysis of IgG antibody patterns against retinal antigens and antibodies to alpha-crystallin, GFAP, and alpha-enolase in sera of patients with "wet" age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245: 619-626. (Pubitemid 46951226)
12. Kasp E, Graham EM, Stanford MR, &, Dumonde DC, (1989): A point prevalence study of 150 patients with idiopathic retinal vasculitis: 2. Clinical relevance of antiretinal autoimmunity and circulating immune complexes. Br J Ophthalmol 73: 722-730. (Pubitemid 19236990)
13. Kubicka-Trzäska A, (2004): Antiretinal antibodies (ARA) in patients with endogenous posterior uveitis in indirect immunofluorescence test. Klin Oczna 106: 45-49.
14. Kubicka-Trzäska A, &, Wilańska J, (2009): [Serum antiretinal antibodies (ARA) in patients with exudative age-related macular degeneration (AMD)-preliminary findings]. Przegl Lek 66: 944-947.
15. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchère E, Coutinho A, &, Kazatchkine MD, (1998): Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216: 117-137. (Pubitemid 28440383)
16. Mullins RF, Russell SR, Anderson DH, &, Hageman GS, (2000): Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14: 835-846. (Pubitemid 30241660)
17. Nowak JZ, (2006): Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 58: 353-563.
18. Nussenblatt R, &, Ferris F, (2007): Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 144: 618-626.
19. Patel N, Ohbayashi M, Nugent AK, et al., (2005): Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology 115: 422-430. (Pubitemid 40896040)
20. Penfold PL, Provis JM, Furby JH, Gatenby PA, &, Billson FA, (1990): Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthlmol 228: 270-274. (Pubitemid 20150313)
21. Sugita S, (2009): Role of pigment epithelial cells in immune privilege. Arch Immunol Ther Exp 57: 263-268.
22. Zarbin MA, (2004): Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122: 598-614. (Pubitemid 38456297)
23. Zhang J, Silva T, Yarovinsky T, et al., (2010): VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 6: 408-417.